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Abstract
Background: We describe histological, clinical findings and outcomes of renal involvement during Leishmania
infantum infection in four HIV-infected patients in South France and North Italy hospital settings.
Cases presentation: Four HIV-infected Caucasian patients (age 24-49) performed renal biopsy during episodes of
visceral leishmaniasis. They presented severe immunosuppression, frequent relapses of visceral leishmaniasis during a
follow-up period of several years and partial or complete recovery of renal function after anti-parasitic treatment. Main
clinical presentations were nephrotic or nephritic syndrome and/or acute renal failure secondary to membranoproliferative
type III glomerulonephritis or acute interstitial nephritis. Clinical outcome was poor, probably as a consequence of
insufficient immuno-virological control of the HIV infection.
Conclusions: Our findings suggest that the main histological findings in case of renal involvement due to Leishmania
infantum infection in HIV-infected patients are type III MPGN and acute interstitial nephritis, with a histological specificity
similar to that observed in canine leishmaniasis. Poor immune status in HIV-infected patients, altering the capacity for
parasite clearance, and prolonged course of chronic active VL in this population may lead to the development of
specific renal lesions.
Background
Leishmaniasis due to Leishmania infantum is a vector-
borne disease which is endemic in Southern Europe
[1-5]. In humans, Leishmania infection gives rise to a
range of presentations (mainly visceral, cutaneous and
mucosal) depending on the species involved and the
effectiveness of the patient’s immune response to the
parasite [2,6,7]. Visceral leishmaniasis (VL) is present in
61 countries across 4 continents where 200 million
people are exposed. Approximately 0.2 to 0.4 million
cases of VL and 0.7 to 1.2 million cases of cutaneous leish-
maniasis occur each year, with 5 countries (India, Nepal,
Bangladesh, Sudan, Brazil) accounting for 90% of these,
whereas the condition remains sporadic in Southern
Europe [1-4]. In immunosuppressed individuals, including
HIV-infected patients, the clinical presentation of VL can
be atypical [8], easily misdiagnosed or mistaken as a flare-
up of the underlying disease. Before the introduction of
combination antiretroviral therapy (cART), the incidence
of VL was higher in HIV-infected patients than in im-
munocompetent subjects, with higher rates of relapse and
mortality [2]. In the cART era, the incidence of VL in the
HIV-infected population has dramatically decreased [9-13].
Moreover, with the longer life expectancy of HIV-infected
individuals, new clinical features of VL have been reported,
such as active chronic VL, characterized by relapses over a
period of several years and continuous circulation of the
parasite in the bloodstream [14].
Renal involvement in HIV-infected patients with VL is
uncommon and few cases have been reported [15-19].
Patients displayed various patterns of clinical and histo-
logical presentation: isolated proteinuria or hematuria,
nephrotic syndrome (proteinuria >2.5 g/day, hypoalbu-
minemia and generalized œdema), nephritic syndrome
(glomerular proteinuria & hematuria, reduced glomeru-
lar filtration rate with varying degrees of azotemia,
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oliguria and hypertension) secondary to membrano-
proliferative glomerulonephritis (MPGN) or amyloidosis,
and acute kidney injury (AKI) secondary to interstitial
nephritis [15-22].
We present a series of four cases of VL due to Leish-
mania infantum with renal involvement in HIV-infected
patients, including histological findings and clinical
outcome. Patients were hospitalized between 1996 and
2012 in Infectious Diseases Hospital departments in the
Alpes-Maritimes, France and in Liguria, Italy, where
Leishmania infantum infection is endemic.
Cases presentation
Case report n° 1
A 40-year-old HIV-infected male patient, born and resid-
ing in the Nice area (Alpes-Maritimes, South-Eastern
France), was admitted to hospital in June 2011 for persis-
tent diarrhœa and weight loss (5 kgs). He had contracted
HIV-infection in 1996, and his previous medical history
included VL in 2000, (with clinical relapses in 2005 and
2009 but no renal involvement), high blood pressure, cere-
bral toxoplasmosis and Kaposi’s sarcoma in 2003, and
pneumocystis pneumonia in 2006. His antiretroviral
regimen included etravirine, darunavir and ritonavir.
The latest CD4 cell count was 114 cells/mm3 (nadir: 46
cells/mm3) and HIV viral load was 162 copies/ml. Com-
pliance with cART had frequently been sub-optimal. He
presented with nephritic syndrome, urine dipstick
analysis revealing proteinuria and hematuria, but no
leukocyturia. Blood pressure was 150/100 mmHg, with
peripheral œdema. All kidney tissue samples were ob-
tained via needle biopsy. Light microscopy examination
showed diffuse hyper-cellularity with thickening of the
glomerular basement membrane, and immunofluores-
cence microscopy revealed IgG, IgM, C3 and C1q mesan-
gial and endo-membranous deposits . According to the
World Health Organisation (WHO) classification, the
histological findings were typical of type III membrano-
proliferative glomerulonephritis (MPGN).
Diagnosis of VL was based on molecular methods
using Leishmania infantum polymerase chain reaction
(PCR) (Taqman technology; Light Cycler target: kineto-
plast mini-circle DNA) on peripheral blood and other
biological samples, i.e. bone marrow, urine and kidney
[23]. In this patient, qualitative PCR was positive in both
urine and peripheral blood. VL relapse was suspected
and liposomal Amphotericine B (l-Ampho-B), 3 mg/kg
daily, initially scheduled for 10 days, was prematurely
discontinued due to deteriorating renal function and
suspected drug-associated tubulopathy. The patient’s
condition gradually improved and secondary VL prophy-
laxis consisting in monthly intravenous pentamidine in-
fusions was initiated. During follow-up, creatinine levels
remained stable and viro-immunological parameters
improved. The patient was re-admitted in October 2013
for another relapse of VL. Poor cART compliance was
suspected. The CD4 T-cell count and plasma HIV-RNA
level were 79 cells/mm3 and 1,500 copies/ml, respectively.
PCR was positive for Leishmania infantum with 992 para-
sites/ml in plasma and 322 parasites/106 cells in bone
marrow. Treatment with l-Ampho-B was started, adapting
dosage to renal function; fever resolved, parasitemia
dropped to 312 parasites/ml and the estimated glomerular
filtration rate (eGFR) remained stable. Antiretroviral treat-
ment was switched from a twice-daily to a once-daily regi-
men, in order to improve compliance. The patient was
discharged and continued secondary VL prophylaxis as an
outpatient with L-Ampho-B.
Table 1 summarizes baseline characteristics, renal
impairment and clinical outcome for all four patients,
while the main histological findings are described in
Table 2.
Case report n° 2
A 35-year-old male patient, HIV-infected since 1997, born
and residing in the Nice area (Alpes-Maritimes, South-
Eastern France), was first admitted to hospital in 1998 with
VL. He was treated with l-Ampho-B and symptoms im-
proved. During the following years, the patient had several
relapses of VL despite various secondary prophylaxis regi-
mens, including l-ampho-B, pentamidine and miltefosine.
In 2004 he was re-admitted with suspected clinical relapse
of VL. His CD4 cell count was 20 cells/mm3 while HIV
viral load exceeded 100,000 copies/ml. Leishmania infan-
tum parasites were found both in colon biopsy samples
and in peripheral blood. Moreover, liver biopsy showed
large macrophages containing Leishmania infantum. An
additional course of l-Ampho-B resulted in clinical recov-
ery and was followed by maintenance therapy. The eGFR
was normal. Compliance with cART was poor and the
CD4 T-cell count remained below 200 cells/mm3.
In 2006 the patient presented with nephrotic syndrome.
C4 and C3 concentrations were normal, while HIV viral
load and CD4 T-cell count were 41,000 copies/ml and 12
cells/mm3, respectively. Leishmania amastigotes were ob-
served on a blood smear. A renewed course of l-ampho-B
resulted in remission of the nephrotic syndrome.
In 2007, the patient was admitted again with œdema, a
weight gain of 4 kgs and dyspnœa. He presented this time
with nephritic syndrome and acute kidney injury. Comple-
ment activity was normal. Gastroscopy and colonoscopy
revealed several parasites in the stomach, duodenum and
colon. Qualitative Leishmania infantum PCR on blood
and gut samples was positive. Histological examination of
kidney tissue showed type III MPGN with free Leishmania
parasites in a capillary lumen (Figure 1A,B,C,D). Moreover,
Leishmania infantum PCR was positive on the biopsy
sample.
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Compliance with antiretroviral treatment remained
poor and in 2008 the patient was admitted to hospital
for the fourth time due to renewed relapse with diar-
rhœa, weight loss and œdema. His HIV-RNA and CD4
T-cell count were 74,000 copies/ml and 200 cells/mm3,
respectively. The patient died due to renal failure despite
anti-parasitic treatment with l-Ampho-B.
Case report n° 3
A 24 year-old female patient, born in Italy and a resident
of the Sanremo area (Liguria, North-Western Italy),
HIV-infected via maternal-fœtal transmission, was ad-
mitted to hospital in 2012 for weight loss and AKI.
At the time of admission, her cART regimen consisted
in etravine, raltegravir and boosted darunavir. The CD4
Table 1 Description of cases of VL with renal injury and outcome
Case 1 Case 2 Case 3 Case 4
Clinical characteristics
Age 40 35 24 49
Years since HIV contamination 15 11 24 16
Years since diagnosis of visceral Leishmaniosis 11 9 2 19
Renal syndrome Nephritic
syndrome
Nephrotic syndrome AKI Nephrotic syndrome
Biology
Leishmania quantitative PCR test (parasites/ml) 6225 (blood) 1700000 (kidney) Not available 11570 (blood)
C4 concentration (normal range 0.14-0.33 g/l) 0.12 Not available 0.14 0.2
Cryoglobulin Positive Not available Positive Positive type 2
HCV serology Negative Negative Negative Positive
HCV viral load in blood (qualitative) - - - Negative
Serum albumin (g/l) at time of diagnosis or
during follow-up
25 22/14 - 20/24
Plasma hyper-gammaglobulinemia Yes Unknown Yes Yes
Platelets >150000 giga/L at time of renal biopsy Yes Yes Yes Yes
Severe clottingdysfunction No No No No
Hepatic function Normal Normal Normal Normal
HIV viral load (copies/ml) 162 41000 2000 < 40
CD4 T-cell count (cells/mm3) 114 12 70 84
CD4 T-cell nadir (cells/mm3) 46 12 50 84
Plasma creatinine concentrations (year, [μmol/l])
diagnosis/follow-up
143/152 2006 (100)/2007 (265)/
2008(488)
154 / 99 55 / 60
CKD-EPI (ml/min/1.73 m2) diagnosis/follow-up 48/47 105 / 90 / 52 69
Urinalysis
Daily proteinuria (g/day) Diagnosis/follow-up 2.1 1.5/2.0/3.0 0.3 / 0.5 2.0 / 0.5
Hematuria/Leukocyturia +/- +/- -/+ -/-




MPGN III and interstitial
nephropathy
Treatment and outcome
VL treatment regimen l-Amph-B,
Pentamidine
l-Amph-B, Pentamidine, l-Amph-B l-Amph-B, Miltéfosime
Miltefosine
Renal outcome Improved Not improved Improved Improved but worsened
at clinical relapse
Patient outcome Partial recovery Died Partial recovery Died
VL: Visceral Leishmaniasis.
PCR: Polymerase Chain Reaction.
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration Equation.
l-Amph-B: liposomal Amphotericine B.
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T-cell count was low (70 cells/mm3) and plasma HIV-
RNA numbered2,000 copies/ml. Previous personal
medical history included pneumocystis pneumonia, œso-
phageal candidiasis, cytomegalovirus retinitis and, more
recently, two episodes of VL over the last two years.
Both episodes were treated with l-Ampho-B followed by
secondary prophylaxis. Several antiretroviral regimens
had been administered, but compliance had never been
satisfactory, viral load had been undetectable during only
a few months and the CD4 T-cell count had consistently
remained below 200 cells/mm3, with a nadir of 50 cells/
mm3. Gastric and lymph node biopsy revealed Leish-
mania infantum, and a renal needle biopsy was per-
formed to investigate AKI associated with proteinuria.
Light microscopy examination showed interstitial neph-
ritis with free Leishmania in interstitial tissue while no
involvement of the glomeruli was observed. Immuno-
fluorescence microscopy revealed a mesangial pattern of
IgG and IgM deposits (Figure 2A,B)
Treatment with l-Ampho-B was started and resulted
in improved eGFR. Antiretroviral treatment was modi-
fied according to genotyping results. The patient was
Table 2 Description of kidney histo-pathological diagnosis
Patient Case 1 Case 2 Case 3 Case 4











Acute interstitial nephritis: edema
associated with interstitial
lymphoplasmocytic infiltration in







Free Leishmania in a capillary
lumen
Tubules are invaded by
lymphocytes and areas of
necrosis are visualized.
Interstitial granuloma. Positive
PCR for Leishmania infantum
in urine and in renal biopsy
Positive PCR for Leishmania
infantum in the renal biopsy
Glomeruli are uninvolved. Free
Leishmania in a capillary lumen
Immunofluorescence Mesangial and
endomembranous
deposits of IgG, IgM,
C3 and C1q
Fine granular deposition of IgG
and C3 in the mesangium and
along the peripheral capillary loops




of IgG and C3
MPGN: Membrano-proliferative glomeruolonephritis.
PCR: Polymerase Chain Reaction.
A B
C D
Figure 1 Main histological findings in patient 2, who had type III membrano-proliferative glomerulonephritis (MPGN). A. Cortical kidney
inflammation (PAS x1000). B. Clusters of circulating Leishmania free parasytes in capillary (arrow) (Trichrome stain x1000). C. Prominent double
contour formations (arrow) (Silver stain x1000). D. Basement membrane spikes (Silver stain x1000).
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discharged and secondary prophylaxis with l-Ampho-B
was continued. A recent outpatient follow-up visit
showed stable renal function, normal urinary sediment
microscopy and proteinuria of 0.53 g/24 hrs. Despite the
persistent clinical relapse-free period, PCR remained
positive on blood (736 parasites/ml) with a CD4 T-cell
count below 200 cells/mm3 while the HIV viral load did
not exceed50 copies/ml.
Case report n° 4
A 49-year-old male patient, born and residing in the
Nice area (Alpes-Maritimes, South-Eastern France), HIV
and hepatitis C (HCV) co-infected since the age of 16,
was admitted to hospital in 2011 for weight loss, œdema
and nephrotic syndrome without hematuria. The eGFR
was normal. VL had been previously diagnosed in 1991
and treated, resulting in symptom resolution.
Laboratory tests upon admission showed undetectable
HCV and HIV viral loads, and a CD4 T-cell count of 84
cells/mm3. The antiretroviral regimen included abacavir,
lamivudine and lopinavir/ritonavir.
Antiparasitic treatment with miltefosine was initi-
ated, resulting in clinical and biological improvement.
Leishmania infantum PCR on blood was negative, but
was positive on urine. Kidney histological findings
showed type III MPGN and interstitial granuloma. with
positive Leishmania infantum PCR on kidney tissue
(Figure 3A,B). Although HCV co-infection may also
cause renal injury, the undetectable HCV viral load
and positive Leishmania infantum PCR suggested that
MPGN was more likely to be linked to VL than to
HCV. One year later, the patient was re-admitted due
to clinical relapse of VL. HIV-RNA on admission was
1,700 copies/ml and CD4 T-cells numbered 78/mm3.
Leishmania infantum PCR on blood was positive
(11,570 parasites/ml). In spite of treatment with l-
Ampho-B, the patient died a few days after admission
due to severe intestinal bleeding.
Discussion
We describe four cases of VL due to Leishmania infantum
in HIV-infected patients in the cART era, with specific
PCR or microscopic proof of renal involvement.
All patients had severe immunosuppression, and had
presented with recurring episodes of clinical relapse of
VL over a follow-up period of several years. Moreover,
A B
Figure 2 Main histological results in patient 3, who presented acute interstitial nephritis without glomerular involvement. A. Acute
interstitial nephritis: oedema associated with an infiltration of interstitial lymphoplasmacytoid cells (Arrowhead). Tubules are invaded by
lymphocytes (Arrow). Glomeruli are uninvolved. (PAS x200). B. Free Leishmania in interstitial tissue (PAS x1000).
A B
Figure 3 Description of renal biopsy results for patient 4, who presented type III MPGN. A. Inflammation within the cortical kidney (PAS
x100). B. Giant cell granuloma. (HE stain x 400).
Vassallo et al. BMC Infectious Diseases 2014, 14:561 Page 5 of 8
http://www.biomedcentral.com/1471-2334/14/561
they had partial or complete recovery of renal function
after anti-parasitic treatment associated with better con-
trol of HIV infection. The main clinical presentations
included nephrotic or nephritic syndrome secondary to
type III MPGN or acute kidney injury secondary to
interstitial nephritis.
According to the WHO classification, based on ultra-
structural alterations in the glomerular basement mem-
brane, MPGN is subdivided into 3 categories: type I
(sub-endothelial deposits), type II (intra-membranous
dense deposits) and type III, where deposits are found in
the sub-endothelial and mesangial region, similarly to
type I, but, in addition, with numerous sub-epithelial
deposits [24]. Histological findings reported in our series
are in line with sporadic cases described in humans and
in studies on dogs, where type III MPGN was the most
commonpattern [15-22,25,26]. Interestingly, free Leish-
mania were observed inside the capillary lumen of two
patients.
MPGN during VL is probably the result of immune
complex deposition occurring during chronic infection
[15,24,27]. However, other mechanisms of injury have been
suggested in dogs: indeed, there is growing evidence that
T-cell migration into the glomeruli and adhesion mole-
cules play a fundamental role in the pathogenesis of certain
immunologically-mediated cases of glomerulonephritis
[27]. Costa et al. [27] found considerably higher numbers
of CD4 T-cells in dogs with VL compared to uninfected
animals, with no relevant associated immune complex
deposition. The number of T-cells was correlated to the
quantity of Leishmania antigen in phagocytic cells,
suggesting that the parasite itself could directly drive
the inflammatory infiltrate in the glomeruli. Enhanced
expression of adhesion molecules, such as P-selectin
and ICAM-1, has also been found in the mesangium
and glomerular capillaries of animals and humans with
VL, thus suggesting that newly migrated platelets could
play a role in the pathogenesis of renal injury. Finally,
diminished apoptosis may be another possible mechan-
ism contributing to the persistence and progression of
glomerular hyper-cellularity [27].
Acute interstitial nephritis was the other presentation
of renal involvement secondary to Leishmania infantum
infection reported in this series. This is probably the
result of parasitic dissemination, as reported by other
authors in a human kidney transplant recipient [19] and
in dogs [25,26]. Tubular necrosis could be secondary to
ischemia due to small vessel obliteration by Leishmania
spp., while haemolysis and necrotizing tubulitis could be
a consequence of parasitic invasion and inflammatory
response [28,29].
The correlation between immunosuppression and clin-
ical relapse of VL has been suggested by Bourgeois
et al., who showed that the persistence of CD4 T-cell
counts <100 cells/mm3 is one of the main risk factors
for relapse [30]. Since the advent of cART, features of
HIV/Leishmania spp. coinfection include a chronic
course of parasitic disease with latent parasitemia and a
high rate of relapse. Bourgeois et al. [14] defined the
condition as “active chronic VL”, where patients have
long-term persistence of circulating Leishmania species
with alternating symptomatic and asymptomatic phases.
As showed by Kubar et al. [31], patients with relapsing
VL generally have lower CD4 T-cell counts than HIV-
infected patients with primary VL, suggesting that in
addition to the T-cell-mediated response, essential at the
time of primary Leishmania infection, supplementary
mechanisms might operate in case of chronic infection.
Patients described in this series received various anti-
parasitic agents including l-Ampho-B, pentamidine and
miltefosine. They all responded, at least partially, but
they sufferedseveral relapses despite secondary prophy-
laxis. Data regarding secondary prophylaxis of VL in
HIV-infected patients are scarce, explaining the absence
of guidelines favouring a particular regimen [32]. There
is no consensus on the management of active chronic
VL. It is currently suggested that parasite detection by
PCR, together with CD4 T-cell count, may guide deci-
sions for prolonging or stopping prophylaxis in HIV-
infected patients [33-36]. Bourgeois et al. suggest that
secondary prophylaxis could be discontinued in patients
taking cART when either 1) PCR remains negative for at
least 6 months and CD4 T-cell count is >200 cells/mm3
or 2) CD4 T-cell count is <200 cells/mm3 but PCR re-
mains negative for at least 18 months [30].
This case series showed that the clinical outcome of VL
and renal injury is associated with viro-immunological
control of HIV infection, suggesting that immune restor-
ation plays a pivotal role in preventing relapse. In this case
series, suboptimal compliance with antiretroviral treat-
ment was probably the main cause of poor immune recov-
ery, as proven by frequent episodes of viral replication
during follow-up. However, VL itself might play a role:
Leishmania co-infection could enhance viral replication
and immune activation, thus contributing to CD4 T-cell
depletion and increasing the risk of reactivation of latent
infections [37,38]. Thus, even patients with successful anti-
retroviral treatment could be at risk for Leishmania re-
activation.
Finally, in this series, patients presented with active
chronic VL progressing over a protracted course, ran-
ging from 2 to 19 years (median 8 yrs). In mixed cryo-
globulinemia due to hepatitis C virus, another condition
mediated by immune complex deposition, vasculitis-
related symptoms, including renal involvement, are
associated with longer duration of HCV infection [39].
Similarly, in active chronic VL, prolonged infection may
be required to develop renal disease.
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Conclusions
Our results suggest that the main histological findings in
case of renal involvement due to Leishmania infantum
infection in HIV-infected patients are type III MPGN and
acute interstitial nephritis, with specific histological fea-
tures similar to those observed in canine leishmaniasis.
Poor immune status in HIV-infected patients, altering the
capacity for parasite clearance, and prolonged course of
chronic active VL in this population may lead to the devel-
opment of these specific renal lesions. These patients
should thus be regularly screened for Leishmania infantum
infection and their renal function closely monitored.
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